Total body and arm bioimpedance in patients with Alzheimer's disease.

PURPOSE OF THE RESEARCH: To analyse body composition of patients with Alzheimer's disease (AD) using total body and localized specific bioelectrical impedance vector analysis (specific BIVA). METHOD: 127 patients (50 men, 78.2±6.3years; 77 women, 81.4±6.8years) with mild to moderate stages of AD were selected from the Geriatric Division, SS. Trinità Hospital of Cagliari (Italy). A sample of 135 healthy age-matched individuals (74 men, 77.4±5.3years; 61 women, 80.4±5.5years) was chosen as control group. Anthropometric measurements were taken and body mass index (BMI) was calculated. Bioelectrical measurements were taken on the right side of the body for both the whole-body and the arm, using a BIA 101 analyser (Akern). Body composition was assessed by means of specific bioelectrical impedance vector analysis (specific BIVA). The comparison between patients and the control group was performed by two-factor analysis of variance and Hotelling's T2 test. RESULTS: In comparison with the control group, patients with AD showed similar anthropometric characteristics, including BMI, but lower lean tissue mass and higher percent fat mass, as indicated by the lower phase angles and longer specific vectors. The same body composition peculiarities were detected considering only the right arm. CONCLUSION: Patients with AD show characteristics - lower lean mass/higher percent fat mass - that can be detected by both total body and localized bioimpedance approaches. This suggests the possibility of a new, quicker and simpler procedure for body composition assessment.

Cognitive Impairment and Age-Related Vision Disorders: Their Possible Relationship and the Evaluation of the Use of Aspirin and Statins in a 65 Years-and-Over Sardinian Population.

Neurological disorders (Alzheimer's disease, vascular and mixed dementia) and visual loss (cataract, age-related macular degeneration, glaucoma, and diabetic retinopathy) are among the most common conditions that afflict people of at least 65 years of age. An increasing body of evidence is emerging, which demonstrates that memory and vision impairment are closely, significantly, and positively linked and that statins and aspirin may lessen the risk of developing age-related visual and neurological problems. However, clinical studies have produced contradictory results. Thus, the intent of the present study was to reliably establish whether a relationship exist between various types of dementia and age-related vision disorders, and to establish whether statins and aspirin may or may not have beneficial effects on these two types of disorders. We found that participants with dementia and/or vision problems were more likely to be depressed and displayed worse functional ability in basic and instrumental activities of daily living than controls. Mini mental state examination scores were significantly lower in patients with vision disorders compared to subjects without vision disorders. A closer association with macular degeneration was found in subjects with Alzheimer's disease than in subjects without dementia or with vascular dementia, mixed dementia, or other types of age-related vision disorders. When we considered the associations between different types of dementia and vision disorders and the use of statins and aspirin, we found a significant positive association between Alzheimer's disease and statins on their own or in combination with aspirin, indicating that these two drugs do not appear to reduce the risk of Alzheimer's disease or improve its clinical evolution and may, on the contrary, favor its development. No significant association in statin use alone, aspirin use alone, or the combination of these was found in subjects without vision disorders but with dementia, and, similarly, none in subjects with vision disorders but without dementia. Overall, these results confirm the general impression so far; namely, that macular degeneration may contribute to cognitive disorders (Alzheimer's disease in particular). In addition, they also suggest that, while statin and aspirin use may undoubtedly have some protective effects, they do not appear to be magic pills against the development of cognitive impairment or vision disorders in the elderly.

Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report.

We report on a case of reversible Pisa syndrome developed after treatment with galantamine in a patient with Alzheimer's disease without previous exposure to neuroleptic or other cholinesterase inhibitors. Complete and persistent resolution of the syndrome was achieved several weeks after botulinum toxin type-A injection.